Business
Jaguar Health Announces Time Change for Friday, August 13th Investor Webcast to 8:00 AM Eastern Time
Registration link for webcast appears belowCompany plans to file Q2 2021 10-Q on August 13, 2021SAN FRANCISCO, CA / ACCESSWIRE / August 10, 2021 / Jaguar
About this update from Jaguar Health, Inc.
[{"type":"text","content":"Registration link for webcast appears belowCompany plans to file Q2 2021 10-Q on August 13, 2021SAN FRANCISCO, CA / ACCESSWIRE / August 10, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) (\"Jaguar\" or the \"Company\") today announced that the Company investor webcast scheduled for Friday, August 13, 2021 will take place at 8:00 a.m. Eastern Time instead of 8:30 a.m.Participation Instructions for WebcastWhen: Friday, August 13, 2021 at 8:00 AM Eastern TimeParticipant Registration & Access Link: Click HereAbout Jaguar Health, Inc., Napo Pharmaceuticals, Inc. & Napo EU S.p.A.Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Our wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and the only oral plant-based prescription medicine approved under FDA Botanical Guidance. Napo Pharmaceuticals' wholly owned Italian subsidiary, Napo EU S.p.A., focuses on expanding crofelemer access in Europe and is the named target of Dragon SPAC S.p.A.For more information about Jaguar, please visit https://jaguar.health. For more information about Napo Pharmaceuticals, visit www.napopharma.com. For more information about Napo EU, visit www.napoeu.com.About Mytesi®Mytesi® (crofelemer delayed release tablets) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi®. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence ...